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pDifferential Effect of Low-Dose Aspirin for Primary Prevention of
Atherosclerotic Events in Diabetes Management: A Subanalysis of the
JPAD Trial
Okada S, Moriimoto T, Ogaw H, et al. Diabetes Care 2011;34:1277-83.
Conclusion: Low-dose aspirin reduces atherosclerotic events predom-
inately in patients with diabetes treated with diet alone and not in patients
treated with oral hyperglycemic agents or with insulin.
Summary: There have been two large trials investigating low-dose
aspirin and its’ ability to reduce cardiovascular events in patients with
diabetes but without known vascular disease. Both were unable to demon-
strate benefit, but both trials had potential flaws. The Prevention of Progres-
sion of Arterial Disease and Diabetes (POPADAD) trial failed to document
a benefit of aspirin in Scottish patients with either type 1 or type 2 diabetes.
However, there were fewer cardiovascular events than anticipated and low
compliance with aspirin (Belch J. BMJ 2008;337:a1840). The second trial,
Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes
(JPAD) trial did demonstrate a 20% reduction in atherosclerotic events with
aspirin but did not reach statistical significance (Ogawa H. JAMA 2008;300:
2134-41). There have also been epidemiologic studies suggesting patients
with diabetes treated with insulin have increased mortality compared to
those receiving oral hypoglycemic agents (OHAs)or managed by diet (
Muggeo M, et al. Diabetologia 1995;38:318-25). It follows patients with
diabetes treated with insulin may be the most likely to benefit from low-dose
aspirin therapy. The authors therefore performed a subanalysis of the JPAD
trial. Their working hypothesis was low-dose aspirin would be beneficial for
primary prevention in patients with diabetes receiving insulin. JPAD was a
randomized, controlled, open label trial. In the trial, 2539 patients with type
2 diabetes and no previous cardiovascular disease were randomly assigned to
low-dose aspirin (81 or 100 mg daily) or to no aspirin. Median follow-up
was 4.4 years. This paper analyzes the differential affects of low-dose aspirin
in preventing atherosclerotic events in groups receiving different types of
diabetic management. At baseline there 326 patients treated with insulin,
1750 treated with OHAs and 463 managed with diet alone. Patients treated
with insulin had the worst glycemic control and the longest history of
diabetes and the highest prevalence of diabetic microangiopathy. Patients
treated with diet alone had the opposite characteristics. Atherosclerotic
events occurred at an incidence of 26.6, 14.6 and 10.4 cases per 1000 person
years respectively in the insulin, OHA, and diet alone groups. In patients
treated with insulin or OHAs, low-dose aspirin did not affect atherosclerotic
events (insulin HR 1.19; 95%CI, 0.6-2.4; and OHA HR, 0.84; 95% CI,
0.57-1.24). In the diet-alone group, however, low-dose aspirin did reduce
atherosclerotic events despite the lowest event rate (HR, 0.21; 95% CI
0.05-0.64).
Comment: The fact aspirin was not effective in preventing atheroscle-
rotic events in patients with diabetes treated with insulin or OHAs is
compatible with recent literature. However, the finding that aspirin was
effective in reducing vascular events in patients treated with diet alone is a
new and a bit surprising. Perhaps in patients with advanced diabetes the
burden of atherosclerosis is such new events are unpreventable by aspirin, or
such patients have some degree of aspirin resistance. The decision to use
aspirin to prevent vascular events in patients with diabetes should consider
not only conventional cardiovascular risk factors, but the stage of the
diabetes as well.
Adapted from Moneta G et al. 2012 Year Book of Vascular Surgery.
Philadelphia, PA: Elsevier; 2012; with permission.
Longevity and Outcomes of Axillary Valve Transplantation for Severe
Lower Extremity Chronic Venous Insufficiency
Kabbani L, Escobar GA, Mansour F, et al. Ann Vasc Surg 2011;25:496-501.
Conclusion: Venous valve transplantation has good initial technical
and symptomatic success but poor long term valve competency and symp-
tom control.
Summary: Venous valve reconstruction using venous valve transplan-
tation with a segment of axillary vein can be used to treat a small subset of
patients with chronic venous insufficiency (CVI) who fail conservative
therapy or more standard techniques of superficial venous surgery. In this
study the authors report their experience with upper extremity to lower
extremity venous valve transplantation for treatment of refractory CVI.
There were 139 complex venous valve reconstructions performed between
1991 and 2007 for CVI, 18 underwent upper extremity to lower extremity
venous valve transplantation. In 13 cases an upper extremity valve was
transplanted to the popliteal vein, to the common femoral vein in 6 cases and
to the saphenofemoral junction in two cases for a total of 21 procedures. All ratients had follow-up with duplex scanning to assess valve competency and
eceived clinical follow-up as well. Mean follow-up was 37 months and 57%
f the patients were men with a mean age of 44 years. Clinically, 57% of the
imbs were CEAP 5-6. The mean preoperative venous disability score was
.95. 66% of the patients had postthrombotic valvular dysfunction and no
roximal venous obstruction was documented in any patient at the time of
alve transplantation. Technical success of the operation was defined as a
ompetent valve at the end of the procedure and was achieved in 20 of 21
ases. Post operative complications, primarily bleeding, occurred in one-
hird of patients. The mean postoperative venous disability score was 2.65
nd this increased to 2.75 (P  ns compared with baseline) at the last
ostoperative visit. Median time to return of symptoms was 12 months and
edian reflux free survival was 15 months.
Comment: Axillary valve transplantation is an example of a theoreti-
ally sound but poorly performing procedure to treat deep venous insuffi-
iency in patients with CVI. The operation is not easy. Some axillary valves
re incompetent. In six of the author’s patients the valves needed to be
epaired at the primary operation to achieve competency. Nearly 75% of the
atients in this series were postthrombotic patients, arguably the most
ifficult subset of patients with refractory CVI. Whereas it appears axillary
alve transplantation does not work well for postthrombotic CVI, there may
e some subsets of patients, ie those with primary deep venous insufficiency,
ho may still potentially benefit from the procedure.
Adapted from Moneta G et al. 2012 Year Book of Vascular Surgery.
hiladelphia, PA: Elsevier; 2012; with permission.
ajor Arterial Aneurysms and Pseudoaneurysms in Behcet’s Disease:
esults from a Single Centre
ho SB, Kim T, Cho, S, et al. Scandinavian Rheumatology 2011;40:64-7.
Conclusion: One-third of patients with Behcet’s disease (BD) and
ith BD related aneurysms will, upon further investigation, be found to have
dditional aneurysms.
Summary: BD is an autoinflammatory, multisystem, vasculitis that
ffects all sizes and types of vessels (Cocco G, et al. Open Cardiovasc Med J
010;4:63-70). BD, however, mostly affects veins, venules and capillaries
Alpagut U, et al. Ann Vasc Surg 2007;21:232-9). Major arterial involve-
ent is infrequent and occurs in only about 1 to 7% of BD patients. Arterial
athology is both arterial occlusions and aneurysm rupture, and it is the
rterial involvement that correlates closely with mortality and morbidity in
D patients. This report focuses on 30 BD patients from Korea diagnosed
ith aneurysms and pseudoaneurysms of major arteries. The focus was on
nitial clinical symptoms, location of aneurysm lesions, and treatment re-
ponses. The data were derived from medical records retrospectively. There
ere 47 aneurysms and pseudoaneurysms in the 30 patients (32 saccular
neurysms, eight fusiform aneurysms, and seven pseudoaneurysms. Most
seudoaneurysms and aneurysms (27 patients, 90%) had not ruptured. Most
atients presented with symptoms (70 %, n 21). One-third of patients had
wo or more aneurysm lesions. Aneurysm recurrence was observed in five
atients after treatment with a stent graft (n 3) graft interposition (n 1)
r embolization (n  1).
Comment: Large artery arteritis is an infrequent, but a major cause of
ortality in BD patients. The article confirms the clinical impression of an
pparent high rate of graft related complications with treatment of BD
neurysms; perhaps related to ongoing inflammation in the BD patient. Of
ost interest is the fact that if you find an aneurysm in a patient with BD, if
ou look further, one-third of the time you will find an additional aneurysm.
herefore patients with BD and a discovered aneurysm essentially require
isualization of their entire arterial system. BD arterial aneurysms can be
ound in virtually any artery from the aortic arch to the pulmonary circula-
ion, as well as in intracranial arteries and the tibial arteries.
Adapted from Moneta G et al. 2012 Year Book of Vascular Surgery.
hiladelphia, PA: Elsevier; 2012; with permission.
ptimizing Protocols for Risk Prediction Asymptomatic Carotid Ste-
osis Using Embolic Signal Detection: The Asymptomatic Carotid
mboli Study
ing A, Shipley M, Marksu H, et al. Stroke 2011;42:2819-24.
Conclusion: Transcranial Doppler (TCD) recordings comprising 2
aseline sessions lasting one hour provide the best prediction of stroke risk in
atients with asymptomatic carotid stenosis.Summary: Randomized clinical trials have demonstrated that stroke
isk can be reduced with prophylactic carotid endarterectomy (CEA). How-
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